title: Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
abstract: Before 2011, patients with advanced or metastatic melanoma had a particularly poor long-term prognosis. Since traditional treatments failed to confer a survival benefit, patients were preferentially entered into clinical trials of investigational agents. A greater understanding of the epidemiology and biology of disease has underpinned the development of newer therapies, including six agents that have been approved in the EU, US and/or Japan: a cytotoxic T-lymphocyte antigen-4 inhibitor (ipilimumab), two programmed cell death-1 receptor inhibitors (nivolumab and pembrolizumab), two BRAF inhibitors (vemurafenib and dabrafenib) and a MEK inhibitor (trametinib). The availability of these treatments has greatly improved the outlook for patients with advanced melanoma; however, a major consideration for physicians is now to determine how best to integrate these agents into clinical practice. Therapeutic decisions are complicated by the need to consider patient and disease characteristics, and individual treatment goals, alongside the different efficacy and safety profiles of agents with varying mechanisms of action. Long-term survival, an outcome largely out of reach with traditional systemic therapies, is now a realistic goal, creating the additional need to re-establish how clinical benefit is evaluated. In this review we summarise the current treatment landscape in advanced melanoma and discuss the promise of agents still in development. We also speculate on the future of melanoma treatment and discuss how combination and sequencing approaches may be used to optimise patient care in the future.
authors.affiliation: Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Centre and Swiss Institute of Bioinformatics, Génopode, Lausanne, Switzerland. Electronic address: olivier.michielin@chuv.ch.
authors.forename: Olivier
authors.initials: O
authors.lastname: Michielin
authors.affiliation: Department of Dermatology, Medical University Vienna, Austria. Electronic address: christoph.hoeller@meduniwien.ac.at.
authors.forename: Christoph
authors.initials: C
authors.lastname: Hoeller
mesh_terms: D000911:Antibodies, Monoclonal / Q000145:classification / Q000494:pharmacology; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D018450:Disease Progression; D004358:Drug Therapy / Q000379:methods / Q000639:trends; D005544:Forecasting; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009367:Neoplasm Staging; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases
keywords: Chemotherapy; Combination; Europe; Immunotherapy; Ipilimumab; Melanoma; Targeted therapy